Researchers conducted a retrospective study published in June 2025 issue of Rheumatology International to compile evidence on sex-specific differences in systemic lupus erythematosus (SLE), focusing ...

Serum S100A8/A9 levels are “significantly higher’ among patients with cognitive impairment in systemic lupus erythematosus, ...

The U.S. Food and Drug Administration has approved GSK's autoinjector of Benlysta (belimumab) for subcutaneous injection in ...

A team studied the differences between monogenic and nonmonogenic lupus nephritis and the predictors of end-stage kidney disease. Monogenic lupus nephritis is distinct from non-monogenic disease with ...

The systemic lupus erythematosus-associated NCF1 90H allele synergizes with viral infection to cause mouse lupus but also limits virus spread The induction of autoimmune symptoms may require both ...

Guidelines recommend minimizing glucocorticoid exposure in patients with lupus (SLE), and research suggests this advice should also apply to those with lupus nephritis.

Dysregulation of the alternative complement pathway, hallmarked by isolated reduction of the serum C3 fraction, is now recognized as an additional feature of lupus nephritis. Persistent, isolated low ...

UCB and Biogen say their first phase 3 trial of their systemic lupus erythematosus (SLE) candidate dapirolizumab pegol was a success, and a second is now expected to start before the end of the year.

About Enpatoran Enpatoran is a selective Toll-like receptor (TLR)7/8 inhibitor under investigation for the treatment of systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE).

Gazyva has also been filed for the lupus nephritis indication in Europe, said Roche, which is also expecting a readout from the phase 3 ALLEGORY trial in a broader SLE population later in 2025 and ...

Some of them focus on managing or improving lupus symptoms, while others focus on offering emotional, social, or spiritual support. Remember, everyone with lupus experiences it differently. The types ...

In the Belimumab in Subjects with Systemic Lupus Erythematosus (BLISS)-BELIEVE Study, combination therapy was not superior to belimumab add-on therapy in non-renal SLE, although a clinical benefit was ...